13/05
2025
Effectiveness of mobile applications in enhancing adverse drug reaction reporting
Adverse drug reactions (ADRs) have a significant impact on the healthcare system worldwide. Underreporting of ADRs is identified as a main issue in pharmacovigilance. Mobile applications(apps) have been introduced as a solution for the underreporting of ADRs. This systematic review was conducted to assess the efficacy of the mobile applications in enhancing ADR reporting.
more
20/05
2025
The role of adverse event follow-up in advancing the knowledge of medicines and vaccines safety: a scoping review
The primary objective of this scoping review is to understand and evaluate the concept, implementation, frequency, and value of "follow-up" in the context of adverse event (AE) assessment. Secondary objectives include providing an overview of various definitions of "follow-up," describing the requirements and studies evaluating follow-up methods, and assessing how often follow-up is undertaken in assessing an AE, by whom, and its value.
more
01/06
2025
Carbamazepine-induced liver injury – a case report
Report of a case of carbamazepine-induced acute hepatocellular liver failure in a patient with trigeminal neuralgia and complete recovery after discontinuation of carbamazepine.
more
12/06
2025
Minimum data set and metadata for active vaccine safety surveillance: systematic review
This review aims to define the minimal data scope for association studies in vaccine safety, providing a reference framework for implementing active vaccine surveillance systems (AVSSs) worldwide, especially in low- and middle-income countries. PubMed, Embase and Web of Science were searched for cohort and case-control studies related to AVSS published between January 1, 2018, and September 7, 2022. Guided by the WHO and CIOMS guidelines, a 4D framework for Minimum Data Sets (MDSs), including “Vaccine,” “Outcome,” “Demographic Data,” and “Covariate”, was developed.
more
30/06
2025
Enhancing pharmacovigilance in pharmaceutical companies: a comparative study of electronic reporting before and after implementation
Since 2016, Moroccan pharmaceutical companies have been required to report adverse effects linked to medicines. Initially, reports were submitted using the CIOMS form, sent by normal mail to le Centre Antipoison et de Pharmacovigilance du Maroc, then using XML files in ICH E2B format, sent electronically. In 2021, a “vigiflow e-reporting for industry” standardized online reporting system was implemented. The primary objective of this study was to evaluate the pharmaceutical companies' use of electronic reporting. Secondarily, the study aimed to assess the quality of adverse drug reaction reports by comparing completeness scores across the three reporting means.
more
01/07
2025
Vulnerability in research ethics: a systematic review of policy guidelines and documents
A systematic review of policy documents was carried out to provide a comprehensive overview of how vulnerability is conceptualized and operationalized in research ethics. The aim was to investigate the meaning and definition of vulnerability in research ethics, its normative justification, the comprehensive set of subjects it refers to, and consequent provisions.
more
07/07
2025
Ethical practices for gaining access for research with deaf communities in South Africa: a case of South African sign language
Research ethics frameworks used in South Africa view deafness from a biomedical perspective. This could hinder research access to deaf communities. Deaf-centric best practices draw from sociocultural perspectives instead. Motivated by this lack of deaf-centric provisions for research with deaf communities in the existing legal ethical frameworks in South Africa, this article examines best practices for gaining access to Deaf communities based on a broader study on South African Sign Language place names.
more